Fecal α1-proteinase inhibitor concentration in dogs receiving long-term nonsteroidal anti-inflammatory drug therapy

Veterinary Clinical Pathology

Volumn 32, Issue 3, 2003, Pages 136-139

  Murphy, K F ^a   German, A J ^a,c   Ruaux, C G ^b   Steiner, J M ^b   Williams, D A ^b   Hall, E J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Dog; NSAID; 1 proteinase inhibitor

Indexed keywords

ALPHA 1 ANTITRYPSIN; CARPROFEN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; CARBAZOLE DERIVATIVE; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; BONE DISEASE; CONTROLLED STUDY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FECES ANALYSIS; FEMALE; GASTROINTESTINAL DISEASE; MALE; NONHUMAN; ANIMAL; ANIMAL DISEASE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CHRONIC DISEASE; DOG DISEASE; FECES; PROTEIN LOSING GASTROENTEROPATHY;

CANIS FAMILIARIS;

ALPHA 1-ANTITRYPSIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARBAZOLES; CASE-CONTROL STUDIES; CHRONIC DISEASE; DOG DISEASES; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; MALE; PROTEIN-LOSING ENTEROPATHIES; THIAZINES; THIAZOLES;

EID: 0142103204     PISSN: 02756382     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-165X.2003.tb00326.x     Document Type: Article

References (17)

1. Thomas DW, Sinatra FR, Merritt RJ. Random fecal alpha-1-antitrypsin concentration in children with gastrointestinal disease. Gastroenterology. 1981;80:776-782.
2. 1-protease inhibitor. Am J Vet Res. 1998;59:127-130.
3. Mohr AJ, Leisewitz LS, Jacobson JM, Steiner JM, Ruaux CG, Williams DA. Effect of early enteral nutrition on intestinal permeability, intestinal protein loss, and outcome in dogs with parvovirosis [abstract]. In: Proc 19th ACVIM Forum. Denver, CO; 2001:840.
4. Vaden SL, Sellon RK, Melgarejo LT, et al. Evaluation of intestinal permeability and gluten sensitivity in Soft-Coated Wheaten Terriers with familial protein-losing enteropathy, protein-losing nephropathy or both. Am J Vet Res. 2000;61:518-524.
5. 1 protease inhibitor in dogs with diet-responsive and other bowel disease and response to treatment [abstract]. In: Proc ESVIM Congress; Dublin, Ireland; 2001:54.
6. 1-PI) concentration as a test for canine protein losing enteropathy (PLE) [abstract]. J Vet Intern Med. 1991;5:133.
7. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology. 1993;104:1832-1847.
8. Sigthorsson G, Tibble J, Hayllar J, et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut. 1998;43:506-511.
9. 1-proteinase inhibitor concentration in dogs with chronic gastrointestinal disease. Vet Clin Pathol. 2003;32:67-72.
10. Fiorucci S, Antonelli E, Morelli A. Mechanism of non-steroidal anti-inflammatory gastropathy. Dig Liver Dis. 2001;33:35-43.
11. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 2000;355:646-648.
12. Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis. 2000;31:S202-S210.
13. Dammann HG. Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity. Z Gastroenterol. 1999;37:45-48.
14. Streppa HK, Jones CJ, Budsberg SC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood. Am J Vet Res. 2002;63:91-94.
15. Kay-Mugford P, Benn SJ, LaMarre J, Conlon P. In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000;61:802-810.
16. Brideau C, Van Staden C, Chan CC. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs and cats. Am J Vet Res. 2001;62:1755-1760.
17. Ricketts AP, Lundy KM, Seibel SB. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res. 1998;59:1441-1446.